How to access Ctexli for cerebrotendinous xanthomatosis from Saudi Arabia: 2026 pathway via KFSHRC metabolic and genetics programmes | Reserve Meds
*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.
Saudi Arabia carries one of the highest documented prevalences of cerebrotendinous xanthomatosis (CTX) in the Gulf because of the underlying consanguinity rate and the long-standing capture of metabolic neurology cases at King Faisal Specialist Hospital and Research Centre (KFSHRC) Riyadh, King Abdulaziz Medical City (KAMC) Riyadh and Jeddah, and King Fahad Medical City (KFMC). A patient with CTX in Saudi Arabia is almost always already in the metabolic genetics or neurology system, not a newcomer. The 2026 question is whether to source Ctexli, the first FDA-approved oral chenodeoxycholic acid replacement therapy, through SFDA registration, MoH personal-import, or named-patient supply.
Why Ctexli, why now
Ctexli received FDA approval in February 2024 as the first treatment specifically labelled for CTX in adults and paediatric patients. CTX is an inborn error of bile-acid synthesis caused by CYP27A1 mutations, with cholestanol accumulation driving progressive neurologic deterioration, tendon xanthomas, juvenile cataracts, and early atherosclerosis. Ctexli is FDA-approved less than 24 months ago, so the Saudi pathway is named-patient or personal-import under SFDA. Domestic registration is not yet in place.
What Ctexli is, in plain language
Ctexli is oral chenodiol (chenodeoxycholic acid) capsules. It replaces the missing bile acid your body cannot make, restoring the feedback signal that suppresses cholestanol production. It does not reverse damage already done. It slows or halts progression and reduces cholestanol. Dosing is weight-based, three times daily with food, for life.
Eligibility at a Saudi metabolic or neurology clinic
The patient must have a confirmed CTX diagnosis: biallelic CYP27A1 pathogenic variants on genetic testing, plus elevated plasma cholestanol. KFSHRC and KAMC both run metabolic genetics services that can confirm. Paediatric cases are managed through paediatric neurology at KFSHRC, KFMC, or Sidra Medicine in Qatar by referral; adults are managed through adult neurology or metabolic clinic.
The Saudi prescribing and supply picture
Ctexli is not SFDA-registered as of 2026. Access is via named-patient import under SFDA's personal medication importation framework or via institutional special-access request from KFSHRC pharmacy. Reserve Meds coordinates the import file, the prescription chain from the treating neurologist or metabolic specialist, and the cold-chain or temperature-controlled shipping from US or EU source.
Cost band
USD 150K-220K annual per patient (SAR 565K-825K), weight-dependent. The drug is dosed three times daily and continued for life. MoH coverage for rare-disease imports is case-by-case under the Council of Health Insurance rare disease policy; private insurance coverage is unusual.
What to expect, week-by-week
Weeks 0 to 4: confirm diagnosis if not already on file, get the prescription, file the import authorisation, place the order. Weeks 4 to 8: shipment arrives, initiation under metabolic-clinic supervision, baseline cholestanol and liver enzymes documented. Weeks 8 to 24: monitor cholestanol trend, liver function, and tolerability; dose adjustments are uncommon. Month 6 and 12: full metabolic and neurologic re-assessment, MRI for white-matter status.
When Ctexli is the wrong drug
If the diagnosis is not biallelic CYP27A1, this is not the drug. If cholestanol is normal, the diagnosis is in question. If the patient already has end-stage neurologic disease, the realistic goal becomes stabilisation rather than reversal; family must be counselled accordingly. Pregnancy data are limited; women of childbearing age need a documented contraception plan.
Closing
Reserve Meds runs the Ctexli import file from the KFSHRC or KAMC metabolic-genetics referral through SFDA named-patient authorisation, US or EU sourcing, and delivered supply. The clinical decision sits with your treating metabolic specialist or neurologist. We handle the rest.
Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating metabolic specialist or neurologist.
Clinical and regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-05-20.
Regulatory status of Ctexli (chenodiol) in Saudi Arabia, 2026
Ctexli (chenodiol) is approved by the US Food and Drug Administration for the labelled indication of cerebrotendinous xanthomatosis (CTX) in adults (see the FDA approval record at accessdata.fda.gov). The European Medicines Agency holds a parallel marketing authorisation where applicable (see the EMA EPAR at ema.europa.eu). For a Saudi Arabia-based patient, the access pathway runs through the Saudi Food and Drug Authority (SFDA) framework. The official regulator portal is at www.sfda.gov.sa/en; the locally registered medicines list is at www.sfda.gov.sa/en/drugs-list.
Where Ctexli (chenodiol) is held on the locally registered list at the time the case opens, standard prescription and in-country dispensing applies and the treating consultant at the prescribing tertiary centre coordinates supply through the institutional pharmacy. Where Ctexli (chenodiol) is not yet on the locally registered list at the time the case opens, the named-patient and personal-import framework that the Saudi Food and Drug Authority (SFDA) maintains for reference-authority-approved medicines is the operative route. The qualifying conditions are well established: the medicine is approved by a recognised reference authority (FDA or EMA qualifies), no locally available alternative is clinically equivalent for the specific patient indication, the treating physician of record takes documented clinical responsibility, and chain of custody is preserved end to end from the US source through international transit to the named dispensing facility. Confirm current registration status at intake; the published registration list governs.
Tertiary centers and clinical coordination in Saudi Arabia
The Saudi Arabia tertiary referral network for a Ctexli (chenodiol) case is concentrated at King Faisal Specialist Hospital and Research Centre (KFSHRC) Riyadh and Jeddah, King Abdulaziz Medical City (KAMC), King Fahad Medical City (KFMC), Princess Noorah Oncology Center, and King Fahd Specialist Hospital Dammam. These centers carry the haematology, oncology, neurology, metabolic, infectious-disease, or rare-disease specialist staffing and the institutional pharmacy and import-license operations that the named-patient pathway requires. For oral bile acid replacement therapy (chenodeoxycholic acid) therapies that require specialised infusion infrastructure, baseline organ-function workup, or post-treatment monitoring of a complexity beyond what a community centre is configured for, the case is routinely referred to one of these tertiary centers from the outset.
For oral, subcutaneous, or in-clinic infusion therapies that can be administered in Saudi Arabia once imported, the tertiary centres dispense and monitor under their institutional pharmacy operations. Reserve Meds handles US-side sourcing under Drug Supply Chain Security Act (DSCSA) chain-of-custody documentation, international shipment to the named dispensing facility, and re-supply cadence aligned to the dosing schedule. For therapies that require US-certified treatment center administration (some cell, gene, and complex biologics fall in this bucket), the practical access pathway runs through patient travel to a US-certified treatment center rather than import into Saudi Arabia; the Saudi Arabia tertiary team continues to handle upstream referral package assembly and the long-term follow-up after the patient returns home.
Saudi Arabia pricing reference and payer posture, 2026
Reserve Meds publishes a drug-only US cash-pay reference range at intake and issues a delivered, itemised quote within 24 hours once the treating physician's documentation is in. The 2026 reference rate used for SAR conversion is 1 USD = 3.750 SAR. As an illustrative composite case in the 2026 reference band, the US cash-pay drug-only cost for Ctexli (chenodiol) reflects the US wholesale acquisition cost published by the manufacturer (Mirum Pharmaceuticals) plus standard specialty pharmacy markup; the precise band is delivered in the case quote because it varies by indication, dosing, and pack size.
Logistics, international shipment, chain-of-custody documentation, cold-chain handling where applicable, Reserve Meds concierge coordination, and any patient and caregiver travel and accommodation are itemised separately. For a complex case the total course cost commonly lands meaningfully above the drug-only band once treatment-centre fees, pre-treatment workup, on-treatment monitoring, complication management, and family logistics are added in.
Payer posture in Saudi Arabia is overwhelmingly cash-pay for named-patient imports and cross-border specialty cases. The relevant public-payer body is CCHI (Council of Cooperative Health Insurance); the portal is at www.cchi.gov.sa. Public coverage generally does not extend to non-locally-registered specialty cases. Private health insurance plans review case-by-case on a pre-authorisation basis when the documentation package is strong, but cash-pay should be assumed as the default at intake.
Access barriers and how Reserve Meds clears them
The five access barriers we see most often for a Ctexli (chenodiol) case in Saudi Arabia are: (1) Regulatory documentation complexity. The Saudi Food and Drug Authority (SFDA) named-patient and personal-import application package requires a specific bundle (physician clinical rationale letter, prescription, patient identifier, product strength and quantity, chain-of-custody plan, evidence of reference-authority approval, and confirmation that no locally available alternative is clinically equivalent for the patient). Reserve Meds provides physician-facing templates that match the format reviewers expect. (2) US-side sourcing and DSCSA chain-of-custody. We coordinate with our US-licensed specialty wholesale partners to secure Ctexli (chenodiol) from authorised distribution under the US Drug Supply Chain Security Act, logging every transfer point through to international shipment.
(3) Clinical eligibility documentation. The treating consultant at the prescribing tertiary centre defines eligibility against the FDA labelled indication and the relevant clinical-practice guideline; Reserve Meds does not adjudicate the clinical decision. (4) Family logistics. Patient and caregiver travel where applicable, accommodation near the treatment center where applicable, in-country transport, translator support where needed, and post-treatment data flow back to the treating Saudi Arabia physician are coordinated as a single arc. (5) Insurance and payer posture. Cash-pay is the default. Where private insurance review is contemplated, we supply documentation for the family's submission but we do not bill insurers and we do not adjudicate insurance disputes.
Drug-specific clinical context for Ctexli (chenodiol): the labelled indication is cerebrotendinous xanthomatosis (CTX) in adults. The oral bile acid replacement therapy (chenodeoxycholic acid) mechanism shapes both the eligibility workup and the monitoring schedule. The relevant clinical-practice guideline body is CTX international consensus statement (J Inherit Metab Dis 2014) and the National Organization for Rare Disorders (NORD) at rarediseases.org/. The treating physician of record makes the clinical decision; Reserve Meds is the coordination layer that clears the operational and regulatory barriers between the prescription and the delivered course.
Recent regulatory and access news for Ctexli (chenodiol) in Saudi Arabia, 2026
The Saudi Food and Drug Authority (SFDA) portal at www.sfda.gov.sa/en and the locally registered medicines list at www.sfda.gov.sa/en/drugs-list are the authoritative source for the current Saudi Arabia listing status of Ctexli (chenodiol); the snapshot date governs. The FDA Drug Safety Communications feed at fda.gov drug-safety-communications and the FDA Drug Shortages list at accessdata.fda.gov drugshortages are the authoritative sources for any active Ctexli (chenodiol) safety advisory or shortage signal over the most recent 12-month window. The FDA labelled indication for Ctexli (chenodiol) remains cerebrotendinous xanthomatosis (CTX) in adults (see the current FDA approval record at accessdata.fda.gov). Mirum Pharmaceuticals continues commercial supply per the FDA-labelled indication and the EMA marketing authorisation. The CTX international consensus statement (J Inherit Metab Dis 2014) and the National Organization for Rare Disorders (NORD) guidance at rarediseases.org/ remains the relevant clinical-practice reference. Reserve Meds refreshes this snapshot per case at intake; the snapshot date governs.